Rigel Pharma (RIGL) Misses Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 +0.35%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.58 million versus the consensus estimate of $3.33 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
